Black Diamond Therapeutics Inc. (BDTX), a clinical-stage oncology company, is scheduled to release two data updates for its lead drug candidate, BDTX-1535, this quarter.
BDTX-1535, which works by inhibiting the mutated EGFR protein involved in cancer cell growth, is currently being tested in the two phase II trials in non-small cell lung cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com